Kevin Roberts, MD
Family Medicine · Little Rock, ARNPI 1336132372
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,727 of the $14,529 with a category attached, or 87.6%. It is spread thinly across 47 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- Amgen$1K
- GSK$1K
- Lilly USA, LLC$1K
- Pfizer$722
- plus $5K from 41 others
Across 180 payments — averaging $14,517 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.4M
- AbbVie$642K
- AstraZeneca$248K
- Novartis$182K
- Pfizer$110K
What the payments were for
- Travel & lodging$1,78712%
- Food & beverage$12,72788%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$212
- BREZTRI$110
- BREZTRI AEROSPHERE$101
- SYMBICORT$101
How this compares
$14,529 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $86,897 |
| OzempicSemaglutide | 55 | $60,465 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $32,475 |
| JardianceEmpagliflozin | 31 | $29,566 |
| EliquisApixaban | 34 | $27,981 |
| FarxigaDapagliflozin Propanediol | 18 | $20,517 |
| RexultiBrexpiprazole | 11 | $16,999 |
| XareltoRivaroxaban | 20 | $14,933 |
| MyrbetriqMirabegron | 12 | $12,483 |
| JanuviaSitagliptin Phosphate | 12 | $10,859 |
| LinzessLinaclotide | 19 | $9,950 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,193 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,332 |
| Gabapentin | 201 | $3,968 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,109 | $86,89781 claims |
| Novo NordiskOzempic | $540 | $60,46555 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,141 | $44,00072 claims |
| Boehringer IngelheimJardiance | $195 | $29,56631 claims |
| PfizerEliquis | $722 | $27,98134 claims |
| AstraZenecaFarxiga, Symbicort | $3,481 | $23,85633 claims |
| Johnson & JohnsonXarelto | $103 | $14,93320 claims |
| AbbVieLinzess, Synthroid | $1,523 | $12,81057 claims |
| Astellas Pharma US IncMyrbetriq | $484 | $12,48312 claims |
| MerckJanuvia | $478 | $10,85912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- Harold BettonLittle Rock$18K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
- Oksana MelnykLittle Rock$12K
- Thomas MooreLittle Rock$11K
- Patrick FieldsLittle Rock$10K
- Gilbert FosterLittle Rock$10K
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.